PMID- 32809265
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20210726
IS  - 1934-6638 (Electronic)
IS  - 1934-662X (Linking)
VI  - 129
IP  - 2
DP  - 2021 Feb
TI  - Evaluation of NR4A3 immunohistochemistry (IHC) and fluorescence in situ 
      hybridization and comparison with DOG1 IHC for FNA diagnosis of acinic cell 
      carcinoma.
PG  - 104-113
LID - 10.1002/cncy.22338 [doi]
AB  - BACKGROUND: Acinic cell carcinoma (AcCC) is diagnostically challenging on 
      fine-needle aspiration because it can mimic several other neoplasms or even 
      normal acinar tissue. Immunopositivity for DOG1, especially circumferential 
      membranous staining, can support the diagnosis of AcCC but is not entirely 
      specific, and it is prone to technical and interpretive challenges on small 
      specimens. NR4A3 (nuclear receptor subfamily 4 group A member 3) translocation 
      and nuclear NR4A3 overexpression were recently described in the majority of 
      AcCCs. Here, the authors evaluate the performance of NR4A3 immunohistochemistry 
      (IHC) and NR4A3 break-apart fluorescence in situ hybridization (FISH) on cell 
      block preparations and compare them with DOG1 IHC in distinguishing AcCC from 
      other entities in the differential diagnosis. METHODS: The authors identified 34 
      cytology cell blocks with lesional cells, including 11 specimens of AcCC (2 of 
      which derived from 1 patient and showed high-grade transformation) as well as 2 
      secretory carcinomas, 7 salivary duct carcinomas, 4 mucoepidermoid carcinomas, 3 
      oncocytomas, 3 renal cell carcinomas, and 6 specimens containing nonneoplastic 
      salivary gland tissue. NR4A3 IHC, DOG1 IHC, and NR4A3 FISH were attempted for all 
      cases. RESULTS: NR4A3 IHC had 81.8% sensitivity and 100% specificity for AcCC, 
      whereas NR4A3 FISH had 36.4% sensitivity and 100% specificity, although 4 cases 
      (3 mucoepidermoid carcinomas and 1 salivary gland tissue sample) could not be 
      analyzed because of low cellularity. Notably, no normal acinar tissue specimens 
      showed NR4A3 positivity by IHC or FISH. In addition, DOG1 IHC had 72.7% 
      sensitivity and 92% specificity. CONCLUSIONS: NR4A3 IHC is highly specific for 
      the diagnosis of AcCC and is more sensitive than DOG1 IHC and NR4A3 FISH. In 
      addition, NR4A3 IHC performance is not improved by the inclusion of DOG1 IHC. 
      Finally, NR4A3 positivity resolves the perennial problem of distinguishing AcCC 
      from normal acinar tissue.
CI  - (c) 2020 American Cancer Society.
FAU - Skaugen, John M
AU  - Skaugen JM
AD  - Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, 
      Pennsylvania.
FAU - Seethala, Raja R
AU  - Seethala RR
AD  - Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, 
      Pennsylvania.
FAU - Chiosea, Simion I
AU  - Chiosea SI
AD  - Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, 
      Pennsylvania.
FAU - Landau, Michael S
AU  - Landau MS
AUID- ORCID: 0000-0002-2871-5409
AD  - Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, 
      Pennsylvania.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200818
PL  - United States
TA  - Cancer Cytopathol
JT  - Cancer cytopathology
JID - 101499453
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (NR4A3 protein, human)
RN  - 0 (Receptors, Steroid)
RN  - 0 (Receptors, Thyroid Hormone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy, Fine-Needle/*methods
MH  - Carcinoma, Acinar Cell/*diagnosis/metabolism
MH  - DNA-Binding Proteins/*metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Receptors, Steroid/*metabolism
MH  - Receptors, Thyroid Hormone/*metabolism
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - DOG1
OT  - acinic cell carcinoma
OT  - cytology
OT  - nuclear receptor subfamily 4 group A member 3 (NR4A3)
OT  - salivary gland
EDAT- 2020/08/19 06:00
MHDA- 2021/07/27 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/06/16 00:00 [received]
PHST- 2020/07/13 00:00 [revised]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - 10.1002/cncy.22338 [doi]
PST - ppublish
SO  - Cancer Cytopathol. 2021 Feb;129(2):104-113. doi: 10.1002/cncy.22338. Epub 2020 
      Aug 18.